The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / TNF Stabilizes Inflammatory RNA in Synoviocytes

TNF Stabilizes Inflammatory RNA in Synoviocytes

August 14, 2017 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Insights into the inflammation that accompanies rheumatoid arthritis (RA) have led to successful therapies, such as tumor necrosis factor (TNF) inhibitors. TNF activates fibroblast-like synoviocytes (FLS) to express multiple genes. Some researchers have proposed that TNF triggers stabilization of transcripts via the induction of molecular pathways that inhibit the mRNA degradation machinery. This hypothesis stands as part of a bigger question that remains unanswered in molecular biology: Is the mRNA degradation rate per gene constant or does it change over time? If TNF were able to stabilize transcripts, then it could theoretically increase translation efficiency—thereby, increasing protein levels. This hypothesis has important implications for RA because, during the course of chronic synovitis, RA FLS express high levels of potentially pathogenic transcripts.

You Might Also Like
  • Anti-TNF-Associated Skin Lesions Common in Inflammatory Bowel Disease
  • Ro60 Autoantigen Regulates Inflammatory Gene Expression
  • TNF Inhibitors Do Not Seem to Boost Cancer-Recurrence Rates
Also By This Author
  • Physical Assessment of Chronic Fatigue Syndrome: It Just May Work

New research from Konstantinos Loupasakis, MD, a rheumatologist at the Hospital for Special Surgery in New York, and colleagues provides the first insights into genome-wide regulation of mRNA stability in RA FLS. The research, published online July 14 in PLosOne, highlights TNFs’ potential contribution to the dynamic regulation of the mRNA stabilome and, thus, its role in chronic synovitis.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“A very interesting finding of our study was the discovery of a temporal switch in the stability states of TNF-induced transcripts in RA FLS,” write the authors in their discussion. “Unstable transcripts dominate the early response to TNF, while during the late TNF response the gene expression program is outbalanced by very stable transcripts. Whereas, transient stabilization of select transcripts can slightly extend transient early expression kinetics in other cell types, such as macrophages, to our knowledge extended stabilization that markedly switches expression kinetics to a sustained pattern is unprecedented.”

The new findings build on the group’s discovery that a single stimulation of FLS with TNF triggers chromatin remodeling. In their current study, the researchers sought to further characterize mRNA stability in the FLS of patients with RA. To do this, they performed a rigorous genome-wide statistical analysis of the genes that were significantly stabilized by TNF. They found that TNF induced a temporal switch by prolonging stabilization of previously unstable transcripts. This TNF-induced mRNA stabilization in RA FLS occurred during the late phase of TNF response. The stabilization allowed for progressive transcript accumulation over three days, as well as sustained expression and late induction of very stable transcripts. Thus, chronic exposure of FLS to TNF appears to increase the mRNA stability status of a wide array of genes, including those with arthritogenic potential.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: fibroblast-like synoviocytes, Rheumatoid Arthritis (RA), RNA, tumor necrosis factor inhibitor

You Might Also Like:
  • Anti-TNF-Associated Skin Lesions Common in Inflammatory Bowel Disease
  • Ro60 Autoantigen Regulates Inflammatory Gene Expression
  • TNF Inhibitors Do Not Seem to Boost Cancer-Recurrence Rates
  • 2015 ACR/ARHP Annual Meeting: Macrophage Polarization and Its Role in Inflammatory Disease

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)